The effect of Mitomycin-C on Molteno implant surgery

Louis Cantor, S. Sanders, V. Bhavnani, J. Hoop, A. Dobler, Alon Harris, Darrell WuDunn

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To assess the effect of adjunctive Mitomycin-C (MMC) in patients undergoing Molteno tube shunt implantation. Methods: 25 eyes of 25 consecutive patients undergoing Molteno implantation were assigned to receive either MMC 0.4 mg/cc in both superior quadrants or a control solution (BSS) in a prospective randomized masked study. Intraocular pressure, vision, and any complications were recorded at 1 week, and 1, 3, 6, and 12 months postoperatively. A 2-sample t-test was used to compare the difference and percent change at each follow-up visit. ANOVA was used to test overall drug effect. Results: 13 eyes received BSS and 12 eyes received MMC. There were no differences noted between the two groups on age or entry IOP. There was no difference between the two groups when comparing the mean difference in IOP from pre-op except at 1 week. There were no differences in complications between the groups. The mean percent decrease in IOP for each group relative to base-line is presented below: 1 wk 1 m 3 m 6 m 1 y BSS 69 44 38 42 73 MMC 87 56 45 46 70 P-Value 0.01 0.33 0.68 0.82 0.86. Conclusion: MMC did not have a significant effect on Molteno implant surgery. Either a different dose of MMC or a different antimetabolite strategy may be necessary to improve the pressure lowering effects of Molteno implantation.

Original languageEnglish
JournalInvestigative Ophthalmology and Visual Science
Volume37
Issue number3
StatePublished - Feb 15 1996

Fingerprint

Molteno Implants
Mitomycin
Antimetabolites
Intraocular Pressure
Analysis of Variance
Age Groups
Pressure

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Cantor, L., Sanders, S., Bhavnani, V., Hoop, J., Dobler, A., Harris, A., & WuDunn, D. (1996). The effect of Mitomycin-C on Molteno implant surgery. Investigative Ophthalmology and Visual Science, 37(3).

The effect of Mitomycin-C on Molteno implant surgery. / Cantor, Louis; Sanders, S.; Bhavnani, V.; Hoop, J.; Dobler, A.; Harris, Alon; WuDunn, Darrell.

In: Investigative Ophthalmology and Visual Science, Vol. 37, No. 3, 15.02.1996.

Research output: Contribution to journalArticle

Cantor, L, Sanders, S, Bhavnani, V, Hoop, J, Dobler, A, Harris, A & WuDunn, D 1996, 'The effect of Mitomycin-C on Molteno implant surgery', Investigative Ophthalmology and Visual Science, vol. 37, no. 3.
Cantor, Louis ; Sanders, S. ; Bhavnani, V. ; Hoop, J. ; Dobler, A. ; Harris, Alon ; WuDunn, Darrell. / The effect of Mitomycin-C on Molteno implant surgery. In: Investigative Ophthalmology and Visual Science. 1996 ; Vol. 37, No. 3.
@article{9de7e505deb349cd81da5823a3ee8a68,
title = "The effect of Mitomycin-C on Molteno implant surgery",
abstract = "Purpose: To assess the effect of adjunctive Mitomycin-C (MMC) in patients undergoing Molteno tube shunt implantation. Methods: 25 eyes of 25 consecutive patients undergoing Molteno implantation were assigned to receive either MMC 0.4 mg/cc in both superior quadrants or a control solution (BSS) in a prospective randomized masked study. Intraocular pressure, vision, and any complications were recorded at 1 week, and 1, 3, 6, and 12 months postoperatively. A 2-sample t-test was used to compare the difference and percent change at each follow-up visit. ANOVA was used to test overall drug effect. Results: 13 eyes received BSS and 12 eyes received MMC. There were no differences noted between the two groups on age or entry IOP. There was no difference between the two groups when comparing the mean difference in IOP from pre-op except at 1 week. There were no differences in complications between the groups. The mean percent decrease in IOP for each group relative to base-line is presented below: 1 wk 1 m 3 m 6 m 1 y BSS 69 44 38 42 73 MMC 87 56 45 46 70 P-Value 0.01 0.33 0.68 0.82 0.86. Conclusion: MMC did not have a significant effect on Molteno implant surgery. Either a different dose of MMC or a different antimetabolite strategy may be necessary to improve the pressure lowering effects of Molteno implantation.",
author = "Louis Cantor and S. Sanders and V. Bhavnani and J. Hoop and A. Dobler and Alon Harris and Darrell WuDunn",
year = "1996",
month = "2",
day = "15",
language = "English",
volume = "37",
journal = "Investigative Ophthalmology and Visual Science",
issn = "0146-0404",
publisher = "Association for Research in Vision and Ophthalmology Inc.",
number = "3",

}

TY - JOUR

T1 - The effect of Mitomycin-C on Molteno implant surgery

AU - Cantor, Louis

AU - Sanders, S.

AU - Bhavnani, V.

AU - Hoop, J.

AU - Dobler, A.

AU - Harris, Alon

AU - WuDunn, Darrell

PY - 1996/2/15

Y1 - 1996/2/15

N2 - Purpose: To assess the effect of adjunctive Mitomycin-C (MMC) in patients undergoing Molteno tube shunt implantation. Methods: 25 eyes of 25 consecutive patients undergoing Molteno implantation were assigned to receive either MMC 0.4 mg/cc in both superior quadrants or a control solution (BSS) in a prospective randomized masked study. Intraocular pressure, vision, and any complications were recorded at 1 week, and 1, 3, 6, and 12 months postoperatively. A 2-sample t-test was used to compare the difference and percent change at each follow-up visit. ANOVA was used to test overall drug effect. Results: 13 eyes received BSS and 12 eyes received MMC. There were no differences noted between the two groups on age or entry IOP. There was no difference between the two groups when comparing the mean difference in IOP from pre-op except at 1 week. There were no differences in complications between the groups. The mean percent decrease in IOP for each group relative to base-line is presented below: 1 wk 1 m 3 m 6 m 1 y BSS 69 44 38 42 73 MMC 87 56 45 46 70 P-Value 0.01 0.33 0.68 0.82 0.86. Conclusion: MMC did not have a significant effect on Molteno implant surgery. Either a different dose of MMC or a different antimetabolite strategy may be necessary to improve the pressure lowering effects of Molteno implantation.

AB - Purpose: To assess the effect of adjunctive Mitomycin-C (MMC) in patients undergoing Molteno tube shunt implantation. Methods: 25 eyes of 25 consecutive patients undergoing Molteno implantation were assigned to receive either MMC 0.4 mg/cc in both superior quadrants or a control solution (BSS) in a prospective randomized masked study. Intraocular pressure, vision, and any complications were recorded at 1 week, and 1, 3, 6, and 12 months postoperatively. A 2-sample t-test was used to compare the difference and percent change at each follow-up visit. ANOVA was used to test overall drug effect. Results: 13 eyes received BSS and 12 eyes received MMC. There were no differences noted between the two groups on age or entry IOP. There was no difference between the two groups when comparing the mean difference in IOP from pre-op except at 1 week. There were no differences in complications between the groups. The mean percent decrease in IOP for each group relative to base-line is presented below: 1 wk 1 m 3 m 6 m 1 y BSS 69 44 38 42 73 MMC 87 56 45 46 70 P-Value 0.01 0.33 0.68 0.82 0.86. Conclusion: MMC did not have a significant effect on Molteno implant surgery. Either a different dose of MMC or a different antimetabolite strategy may be necessary to improve the pressure lowering effects of Molteno implantation.

UR - http://www.scopus.com/inward/record.url?scp=33750195904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750195904&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33750195904

VL - 37

JO - Investigative Ophthalmology and Visual Science

JF - Investigative Ophthalmology and Visual Science

SN - 0146-0404

IS - 3

ER -